Teva Pharmaceuticals CEO on Sales Beat, Branded Drug Strategy, and API Business

Teva's Q3 Performance and Growth Drivers

• 📈 Teva Pharmaceuticals reported a strong Q3 with total revenue of $4.48 billion, exceeding consensus estimates.
• 💡 The significant growth driver was the innovative portfolio, which saw a 33% increase, contributing over $800 million.
• 🚀 Key drugs within the innovative portfolio include Austedo (up 38%), Ajovy (up 19%), and another treatment for schizophrenia (up 24%).

Strategic Transition and Generics Business

• 🎯 Teva is transitioning from a primarily generics company to a world-class biopharma company with a focus on branded medications.
• 📊 While the generics business grew 2%, it missed estimates; however, Teva views its performance over a two-year horizon, expecting a 2% CAGR going forward.
• 💰 The revenue and cash generated from the generics business are crucial for fueling the company's pipeline development.

Future Pipeline and GLP-1 Market

• 🌟 Teva has a robust late-stage innovative pipeline, with new treatments for schizophrenia, asthma, rare diseases (SMA), and IBD planned for release in the coming years.
• 💊 In the GLP-1 market for weight loss, Teva has launched Viktto and will launch s by year-end, but is partnering for larger upcoming GLP-1 products due to manufacturing investment considerations.
• 🔬 The company also anticipates launching over 10 biosimilars in the short to medium term.

Active Pharmaceutical Ingredients (API) Business Divestiture

• ⚠️ Teva is still seeking to divest its active ingredients business, which is the second-largest API business globally and not based in China or India.
• 🤝 The divestiture requires careful consideration of long-term service agreements, as Teva will continue to rely on the business for API supply.
• ⏳ The need for a quick sale has diminished as Teva has strengthened its financial position, allowing for a more thoughtful approach to secure the right deal for shareholders.